Safety of Sofosbuvir and Daclatasvir in Patients having Ischemic Heart Disease for Treatment of HCV Compensated Cirrhosis |Biomedgrid
Journal: American Journal of Biomedical Science & Research (Vol.9, No. 4)Publication Date: 2020-07-06
Authors : Ahmed Rezq; Mahmoud Hazem; Nerin Okasha; Ashraf Zaky; Mohamed Aly;
Page : 340-345
Keywords : HCV ischemic patients; Sofosbuvir in ischemia; CIMT; Medical; Liver transplantation;
Abstract
Various biomarkers were used to evaluate the progression and prognosis of atherosclerosis. Safety of new therapeutic modalities of HCV needs more systematic studies. 80 patients were enrolled in our study to demonstrate the safety margin of the the new treatment of HCV in the form of Sofosbuvir and Daclatasvir in patients with coronary artery disease. CIMT, as well as different biomarkers that predict progression of atherosclerosis were analyzed at the beginning of therapy and after receiving the final dose.
Other Latest Articles
- Left Ventricle Apical Fibroelastoma: A Rare Finding |Biomedgrid
- Uncommon brain metastases from endometrial adenocarcinoma, 2 Case reports |Biomedgrid
- Advanced Laboratory Investigations Conducted at Medical Research Unit Laboratory, MHWT, Uttara Model Town, Dhaka, Bangladesh |Biomedgrid
- A Cautionary Note for COVID-19 Survivors: Potential Long-term Risk for Alzheimer’s Disease |Biomedgrid
- Covid-19 and Its Gastrointestinal Implications |Biomedgrid
Last modified: 2023-06-19 21:23:26